leisure time -WSS

leisure time

author：explore 2025-10-02 22:00:24 - browse：24281

This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.

I have one more, admittedly braggy thing to say about last week’s STAT Breakthrough Summit West in San Francisco. Of course we curated an incredible roster of influential industry leaders to speak on stage. That’s what STAT does. But just as remarkable were the health care and health tech A-Listers who just showed up as summit attendees to listen and learn from their peers — like 23AndMe’s Anne Wojcicki. Please join us in San Francisco next year, or better yet, register for our next summit in Boston, Oct. 16-17.

I’m back in Boston from San Francisco, but flying out again next week, this time to Chicago for the annual meeting of the American Society of Clinical Oncology. How can we be knocking on June, already?

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： RSV vaccines may be linked to small increased risk of developing GBS

entertainment

WSS

Wayne Brady comes out as pansexual: 'Free to love whomever I want'

Scientists unlock the key to scar

FDA does about

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

Change Healthcare cyberattack outage could last weeks

explore

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

entertainment

State Dept. review finds Biden bears some blame for Afghanistan failures

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

Anesthesiologist group: stop taking Ozempic before surgery

Emergent cuts jobs, executive role in business shake

How to save PrEP access — and even expand it

Man killed during FBI raid in connection with threats against Biden, other officials

Trump demands the U.S. pay no more for drugs than other countries … again

ALS groups 'won't be played again' by the FDA, drug sponsors

State Dept. review finds Biden bears some blame for Afghanistan failures

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

hotspot

Why getting cancer drugs just got harder for rural patients

Maui's cultural, historic landmarks damaged in the devastating wildfires

Kenai launches with $82 million for Parkinson’s stem cell therapy

South Korea throws huge K

International team creates first chimeric human

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Wikipedia

entertainment

Wikipedia

focus